

1 **Kratom Revisions**

2026 GENERAL SESSION

STATE OF UTAH

Chief Sponsor:

Sponsor:

3 **LONG TITLE**4 **General Description:**

5 This bill amends provisions related to kratom.

6 **Highlighted Provisions:**

7 This bill:

8 ▶ defines terms;
9 ▶ schedules 7-hydroxymitragynine, including synthetics, if the 7-hydroxymitragynine
10 concentration exceeds a certain percentage as a schedule I controlled substance; and
11 ▶ schedules Mitragynine pseudoindoxyl, including synthetics.12 **Money Appropriated in this Bill:**

13 None

14 **Other Special Clauses:**

15 This bill provides a special effective date.

16 **Utah Code Sections Affected:**17 **AMENDS:**18 **4-45-104**, as enacted by Laws of Utah 2019, Chapter 329
19 **58-37-2**, as last amended by Laws of Utah 2025, Chapter 396
20 **58-37-4**, as last amended by Laws of Utah 2025, Chapter 216

22 *Be it enacted by the Legislature of the state of Utah:*23 Section 1. Section **4-45-104** is amended to read:24 **4-45-104 . Kratom processor requirements -- Criminal penalty.**25 (1) A kratom processor may not prepare, distribute, sell, or offer for sale a kratom product:
26 (a) that is mixed or packed with a nonkratom substance that affects the quality or
27 strength of the kratom product to such a degree as to render the kratom product
28 injurious to a consumer;
29 (b) that contains a poisonous or otherwise deleterious nonkratom ingredient, including a
30 controlled substance as defined in Section 58-37-2;

31 (c) [eontaining a level of 7-hydroxymitragynine in the alkaloid fraction that is greater
32 than 2% of the alkaloid composition of the kratom product] that would be considered
33 a controlled substance under Section 58-37-4;

34 (d) containing a synthetic alkaloid, including synthetic mitragynine, synthetic
35 7-hydroxymitragynine, or any other synthetically derived compound of the kratom
36 plant; or

37 (e) that does not include a product label on the kratom product packaging that states the
38 amount of mitragynine and 7-hydroxymitragynine contained in the packaged kratom
39 product.

40 (2) A kratom processor who violates Subsection (1) is guilty of a class C misdemeanor for
41 each violation.

42 (3) A kratom processor does not violate Subsection (1) if the kratom processor shows by a
43 preponderance of the evidence that the kratom processor relied in good faith upon the
44 representation of a manufacturer, processor, packer, or distributor of food represented to
45 be a kratom product.

46 (4) A kratom processor may not prepare, distribute, sell, or offer for sale a kratom product
47 that is not registered with the department in accordance with this chapter.

48 (5) A kratom processor shall register as a food establishment in accordance with Section
49 4-5-301.

50 Section 2. Section **58-37-2** is amended to read:

51 **58-37-2 . Definitions.**

52 (1) As used in this chapter:

53 (a) "Administer" means the direct application of a controlled substance, whether by
54 injection, inhalation, ingestion, or any other means, to the body of a patient or
55 research subject by:
56 (i) a practitioner or, in the practitioner's presence, by the practitioner's authorized
57 agent; or
58 (ii) the patient or research subject at the direction and in the presence of the
59 practitioner.

60 (b) "Agent" means an authorized person who acts on behalf of or at the direction of a
61 manufacturer, distributor, or practitioner but does not include a motor carrier, public
62 warehouseman, or employee of any of them.

63 (c) "Consumption" means ingesting or having any measurable amount of a controlled
64 substance in a person's body, but this Subsection (1)(c) does not include the

65 metabolite of a controlled substance.

66 (d) "Continuing criminal enterprise" means any individual, sole proprietorship,
67 partnership, corporation, business trust, association, or other legal entity, and any
68 union or groups of individuals associated in fact although not a legal entity, and
69 includes illicit as well as licit entities created or maintained for the purpose of
70 engaging in conduct which constitutes the commission of episodes of activity made
71 unlawful by this chapter, Chapter 37a, Utah Drug Paraphernalia Act, Chapter 37b,
72 Imitation Controlled Substances Act, Chapter 37c, Utah Controlled Substance
73 Precursor Act, or Chapter 37d, Clandestine Drug Lab Act, which episodes are not
74 isolated, but have the same or similar purposes, results, participants, victims, methods
75 of commission, or otherwise are interrelated by distinguishing characteristics. Taken
76 together, the episodes shall demonstrate continuing unlawful conduct and be related
77 either to each other or to the enterprise.

78 (e) "Control" means to add, remove, or change the placement of a drug, substance, or
79 immediate precursor under Section 58-37-3.

80 (f)(i) "Controlled substance" means a drug or substance:

- 81 (A) included in Schedules I, II, III, IV, or V of Section 58-37-4;
- 82 (B) included in Schedules I, II, III, IV, or V of the federal Controlled Substances
83 Act, Title II, P.L. 91-513;
- 84 (C) that is a controlled substance analog; or
- 85 (D) listed in Section 58-37-4.2.

86 (ii) "Controlled substance" does not include:

- 87 (A) distilled spirits, wine, or malt beverages, as those terms are defined in Title
88 32B, Alcoholic Beverage Control Act;
- 89 (B) any drug intended for lawful use in the diagnosis, cure, mitigation, treatment,
90 or prevention of disease in human or other animals, which contains ephedrine,
91 pseudoephedrine, norpseudoephedrine, or phenylpropanolamine if the drug is
92 lawfully purchased, sold, transferred, or furnished as an over-the-counter
93 medication without prescription; or
- 94 (C) dietary supplements, vitamins, minerals, herbs, or other similar substances
95 including concentrates or extracts, which:
 - 96 (I) are not otherwise regulated by law; and
 - 97 (II) may contain naturally occurring amounts of chemical or substances listed
98 in this chapter, or in rules adopted pursuant to Title 63G, Chapter 3, Utah

Administrative Rulemaking Act.

(g)(i) "Controlled substance analog" means:

- (A) a substance the chemical structure of which is substantially similar to the chemical structure of a controlled substance listed in Schedules I and II of Section 58-37-4, a substance listed in Section 58-37-4.2, or in Schedules I and II of the federal Controlled Substances Act, Title II, P.L. 91-513;
- (B) a substance that has a stimulant, depressant, or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant, or hallucinogenic effect on the central nervous system of controlled substances listed in Schedules I and II of Section 58-37-4, substances listed in Section 58-37-4.2, or substances listed in Schedules I and II of the federal Controlled Substances Act, Title II, P.L. 91-513; or
- (C) A substance that, with respect to a particular individual, is represented or intended to have a stimulant, depressant, or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant, or hallucinogenic effect on the central nervous system of controlled substances listed in Schedules I and II of Section 58-37-4, substances listed in Section 58-37-4.2, or substances listed in Schedules I and II of the federal Controlled Substances Act, Title II, P.L. 91-513.

(ii) "Controlled substance analog" does not include:

- (A) a controlled substance currently scheduled in Schedules I through V of Section 58-37-4;
- (B) a substance for which there is an approved new drug application;
- (C) a substance with respect to which an exemption is in effect for investigational use by a particular person under Section 505 of the Food, Drug, and Cosmetic Act, 21 U.S.C. 355, to the extent the conduct with respect to the substance is permitted by the exemption;
- (D) any substance to the extent not intended for human consumption before an exemption takes effect with respect to the substance;
- (E) any drug intended for lawful use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals, which contains ephedrine, pseudoephedrine, norpseudoephedrine, or phenylpropanolamine if the drug is lawfully purchased, sold, transferred, or furnished as an over-the-counter medication without prescription; or

133 (F) dietary supplements, vitamins, minerals, herbs, or other similar substances
134 including concentrates or extracts, which are not otherwise regulated by law,
135 which may contain naturally occurring amounts of chemical or substances
136 listed in this chapter, or in rules adopted pursuant to Title 63G, Chapter 3, Utah
137 Administrative Rulemaking Act.

138 (h)(i) "Conviction" means a determination of guilt by verdict, whether jury or bench,
139 or plea, whether guilty or no contest, for any offense proscribed by:

140 (A) this chapter;
141 (B) Chapter 37a, Utah Drug Paraphernalia Act;
142 (C) Chapter 37b, Imitation Controlled Substances Act;
143 (D) Chapter 37c, Utah Controlled Substance Precursor Act; or
144 (E) Chapter 37d, Clandestine Drug Lab Act; or

145 (ii) for any offense under the laws of the United States and any other state which, if
146 committed in this state, would be an offense under:

147 (A) this chapter;
148 (B) Chapter 37a, Utah Drug Paraphernalia Act;
149 (C) Chapter 37b, Imitation Controlled Substances Act;
150 (D) Chapter 37c, Utah Controlled Substance Precursor Act; or
151 (E) Chapter 37d, Clandestine Drug Lab Act.

152 (i) "Counterfeit substance" means:

153 (i) any controlled substance or container or labeling of any controlled substance that:
154 (A) without authorization bears the trademark, trade name, or other identifying
155 mark, imprint, number, device, or any likeness of them, of a manufacturer,
156 distributor, or dispenser other than the person or persons who in fact
157 manufactured, distributed, or dispensed the substance which falsely purports to
158 be a controlled substance distributed by any other manufacturer, distributor, or
159 dispenser; and

160 (B) a reasonable person would believe to be a controlled substance distributed by
161 an authorized manufacturer, distributor, or dispenser based on the appearance
162 of the substance as described under Subsection (1)(i)(i)(A) or the appearance of
163 the container of that controlled substance; or

164 (ii) any substance other than under Subsection (1)(i)(i) that:

165 (A) is falsely represented to be any legally or illegally manufactured controlled
166 substance; and

167 (B) a reasonable person would believe to be a legal or illegal controlled substance.

168 (j) "Deliver" or "delivery" means the actual, constructive, or attempted transfer of a

169 controlled substance or a listed chemical, whether or not an agency relationship exists.

170 (k) "Department" means the Department of Commerce.

171 (l) "Depressant or stimulant substance" means:

172 (i) a drug which contains any quantity of barbituric acid or any of the salts of

173 barbituric acid;

174 (ii) a drug which contains any quantity of:

175 (A) amphetamine or any of its optical isomers;

176 (B) any salt of amphetamine or any salt of an optical isomer of amphetamine; or

177 (C) any substance which the Secretary of Health and Human Services or the

178 Attorney General of the United States after investigation has found and by

179 regulation designated habit-forming because of its stimulant effect on the

180 central nervous system;

181 (iii) lysergic acid diethylamide; or

182 (iv) any drug which contains any quantity of a substance which the Secretary of

183 Health and Human Services or the Attorney General of the United States after

184 investigation has found to have, and by regulation designated as having, a

185 potential for abuse because of its depressant or stimulant effect on the central

186 nervous system or its hallucinogenic effect.

187 (m) "Dispense" means the delivery of a controlled substance by a pharmacist to an

188 ultimate user pursuant to the lawful order or prescription of a practitioner, and

189 includes distributing to, leaving with, giving away, or disposing of that substance as

190 well as the packaging, labeling, or compounding necessary to prepare the substance

191 for delivery.

192 (n) "Dispenser" means a pharmacist who dispenses a controlled substance.

193 (o) "Distribute" means to deliver other than by administering or dispensing a controlled

194 substance or a listed chemical.

195 (p) "Distributor" means a person who distributes controlled substances.

196 (q) "Division" means the Division of Professional Licensing created in Section 58-1-103.

197 (r)(i) "Drug" means:

198 (A) a substance recognized in the official United States Pharmacopoeia, Official

199 Homeopathic Pharmacopoeia of the United States, or Official National

200 Formulary, or any supplement to any of them, intended for use in the

diagnosis, cure, mitigation, treatment, or prevention of disease in humans or animals;

(B) a substance that is required by any applicable federal or state law or rule to be dispensed by prescription only or is restricted to administration by practitioners only;

(C) a substance other than food intended to affect the structure or any function of the body of humans or other animals; and

(D) substances intended for use as a component of any substance specified in Subsections (1)(r)(i)(A), (B), and (C).

(ii) "Drug" does not include dietary supplements.

(iii) "Drug" includes a food intended for human consumption that intentionally contains a vaccine or vaccine material as provided in Section 4-5-107.

(s) "Drug dependent person" means any individual who unlawfully and habitually uses any controlled substance to endanger the public morals, health, safety, or welfare, or who is so dependent upon the use of controlled substances as to have lost the power of self-control with reference to the individual's dependency.

(t)(i) "Food" means:

(A) any nutrient or substance of plant, mineral, or animal origin other than a drug as specified in this chapter, and normally ingested by human beings; and

(B) foods for special dietary uses as exist by reason of a physical, physiological, pathological, or other condition including the conditions of disease, convalescence, pregnancy, lactation, allergy, hypersensitivity to food, underweight, and overweight; uses for supplying a particular dietary need which exist by reason of age including the ages of infancy and childbirth, and also uses for supplementing and for fortifying the ordinary or unusual diet with any vitamin, mineral, or other dietary property for use of a food.

(ii) Any particular use of a food is a special dietary use regardless of the nutritional purposes.

(u) "Immediate precursor" means a substance which the Attorney General of the United States has found to be, and by regulation designated as being, the principal compound used or produced primarily for use in the manufacture of a controlled substance, or which is an immediate chemical intermediary used or likely to be used in the manufacture of a controlled substance, the control of which is necessary to prevent, curtail, or limit the manufacture of the controlled substance.

235 (v) "Indian" means a member of an Indian tribe.

236 (w) "Indian religion" means a religion:

237 (i) the origin and interpretation of which is from within a traditional Indian culture or

238 community; and

239 (ii) that is practiced by Indians.

240 (x) "Indian tribe" means any tribe, band, nation, pueblo, or other organized group or

241 community of Indians, including any Alaska Native village, which is legally

242 recognized as eligible for and is consistent with the special programs, services, and

243 entitlements provided by the United States to Indians because of their status as

244 Indians.

245 (y) "Manufacture" means the production, preparation, propagation, compounding, or

246 processing of a controlled substance, either directly or indirectly by extraction from

247 substances of natural origin, or independently by means of chemical synthesis or by a

248 combination of extraction and chemical synthesis.

249 (z) "Manufacturer" includes any person who packages, repackages, or labels any

250 container of any controlled substance, except pharmacists who dispense or compound

251 prescription orders for delivery to the ultimate consumer.

252 (aa)(i) "Marijuana" means all species of the genus cannabis and all parts of the genus,

253 whether growing or not, including:

254 (A) seeds;

255 (B) resin extracted from any part of the plant, including the resin extracted from

256 the mature stalks;

257 (C) every compound, manufacture, salt, derivative, mixture, or preparation of the

258 plant, seeds, or resin;

259 (D) any synthetic equivalents of the substances contained in the plant cannabis

260 sativa or any other species of the genus cannabis which are chemically

261 indistinguishable and pharmacologically active; and

262 (E) any component part or cannabinoid extracted or isolated from the plant,

263 including extracted or isolated tetrahydrocannabinols.

264 (ii) "Marijuana" does not include:

265 (A) the mature stalks of the plant;

266 (B) fiber produced from the stalks;

267 (C) oil or cake made from the seeds of the plant;

268 (D) except as provided in Subsection (1)(aa)(i), any other compound,

manufacture, salt, derivative, mixture, or preparation of the mature stalks, fiber, oil or cake;

(E) the sterilized seed of the plant which is incapable of germination;

(F) any compound, mixture, or preparation approved by the federal Food and Drug Administration under the federal Food, Drug, and Cosmetic Act, 21 U.S.C. Sec. 301 et seq. that is not listed in a schedule of controlled substances in Section 58-37-4 or in the federal Controlled Substances Act, Title II, P. 91-513; or

(G) transportable industrial hemp concentrate as that term is defined in Section 4-41-102.

(bb) "Money" means officially issued coin and currency of the United States or any foreign country.

(cc) "Narcotic drug" means any of the following, whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis:

(i) opium, coca leaves, and opiates;

(ii) a compound, manufacture, salt, derivative, or preparation of opium, coca leaves, or opiates;

(iii) opium poppy and poppy straw; or

(iv) a substance, and any compound, manufacture, salt, derivative, or preparation of the substance, which is chemically identical with any of the substances referred to in Subsection (1)(cc)(i), (ii), or (iii), except narcotic drug does not include decocainized coca leaves or extracts of coca leaves which do not contain cocaine or ecgonine.

(dd) "Negotiable instrument" means documents, containing an unconditional promise to pay a sum of money, which are legally transferable to another party by endorsement or delivery.

(ee) "Opiate" means any drug or other substance having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having addiction-forming or addiction-sustaining liability.

(ff) "Opium poppy" means the plant of the species *papaver somniferum* L., except the seeds of the plant.

(gg) "Person" means any corporation, association, partnership, trust, other institution or entity or one or more individuals

303 (hh) "Poppy straw" means all parts, except the seeds, of the opium poppy, after mowing.

304 (ii) "Possession" or "use" means the joint or individual ownership, control, occupancy,

305 holding, retaining, belonging, maintaining, or the application, inhalation, swallowing,

306 injection, or consumption, as distinguished from distribution, of controlled

307 substances and includes individual, joint, or group possession or use of controlled

308 substances. For a person to be a possessor or user of a controlled substance, it is not

309 required that the person be shown to have individually possessed, used, or controlled

310 the substance, but it is sufficient if it is shown that the person jointly participated with

311 one or more persons in the use, possession, or control of any substances with

312 knowledge that the activity was occurring, or the controlled substance is found in a

313 place or under circumstances indicating that the person had the ability and the intent

314 to exercise dominion and control over the controlled substance.

315 (jj) "Practitioner" means a physician, dentist, naturopathic physician, veterinarian,

316 pharmacist, scientific investigator, pharmacy, hospital, or other person licensed,

317 registered, or otherwise permitted to distribute, dispense, conduct research with

318 respect to, administer, or use in teaching or chemical analysis a controlled substance

319 in the course of professional practice or research in this state.

320 (kk) "Prescribe" means to issue a prescription:

321 (i) orally or in writing; or

322 (ii) by telephone, facsimile transmission, computer, or other electronic means of

323 communication as defined by division rule.

324 (ll) "Prescription" means an order issued:

325 (i) by a licensed practitioner, in the course of that practitioner's professional practice

326 or by collaborative pharmacy practice agreement; and

327 (ii) for a controlled substance or other prescription drug or device for use by a patient

328 or an animal.

329 (mm) "Production" means the manufacture, planting, cultivation, growing, or harvesting

330 of a controlled substance.

331 (nn) "Securities" means any stocks, bonds, notes, or other evidences of debt or of

332 property.

333 (oo) "State" means the state of Utah.

334 (pp) "Total kratom alkaloid composition" means the total amount of all alkaloids derived

335 from the Mitragyna speciosa plant.

336 [(pp)] (qq) "Ultimate user" means any person who lawfully possesses a controlled

337 substance for the person's own use, for the use of a member of the person's
338 household, or for administration to an animal owned by the person or a member of
339 the person's household.

340 (2) If a term used in this chapter is not defined, the definition and terms of Title 76, Utah
341 Criminal Code, shall apply.

342 Section 3. Section **58-37-4** is amended to read:

343 **58-37-4 . Schedules of controlled substances -- Schedules I through V -- Findings
344 required -- Specific substances included in schedules.**

345 (1) There are established five schedules of controlled substances known as Schedules I, II,
346 III, IV, and V which consist of substances listed in this section.

347 (2) Schedules I, II, III, IV, and V consist of the following drugs or other substances by the
348 official name, common or usual name, chemical name, or brand name designated:

349 (a) Schedule I:

350 (i) Unless specifically excepted or unless listed in another schedule, any of the
351 following opiates, including their isomers, esters, ethers, salts, and salts of
352 isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and
353 salts is possible within the specific chemical designation:

354 (A) Acetyl-alpha-methylfentanyl

355 (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);

356 (B) Acetyl fentanyl: (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);

357 (C) Acetymethadol;

358 (D) Acryl fentanyl (N-(1-Phenethylpiperidin-4-yl)-N-phenylacrylamide);

359 (E) Allylprodine;

360 (F) Alphacetylmethadol, except levo-alphacetylmethadol also known as
361 levo-alpha-acetylmethadol, levomethadol acetate, or LAAM;

362 (G) Alphameprodine;

363 (H) Alphamethadol;

364 (I) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl]
365 propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);

366 (J) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-
367 piperidinyl]-N-phenylpropanamide);

368 (K) Benzylpiperazine;

369 (L) Benzethidine;

370 (M) Betacetylmethadol;

371 (N) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-
372 piperidinyl]-N-phenylpropanamide);
373 (O) Beta-hydroxy-3-methylfentanyl, other name: N-[1-(2-hydroxy-2-
374 phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide;
375 (P) Betameprodine;
376 (Q) Betamethadol;
377 (R) Betaprodine;
378 (S) Butyryl fentanyl (N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylbutyramide);
379 (T) Clonitazene;
380 (U) Cyclopropyl fentanyl
381 (N-(1-Phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);
382 (V) Dextromoramide;
383 (W) Diampromide;
384 (X) Diethylthiambutene;
385 (Y) Difenoxin;
386 (Z) Dimenoxadol;
387 (AA) Dimepheptanol;
388 (BB) Dimethylthiambutene;
389 (CC) Dioxaphetyl butyrate;
390 (DD) Dipipanone;
391 (EE) Ethylmethylthiambutene;
392 (FF) Etizolam
393 (1-Methyl-6-o-chlorophenyl-8-ethyl-4H-s-triazolo[3,4-c]thieno[2,3-e]1,4-diazepine);
394 (GG) Etonitazene;
395 (HH) Etoxeridine;
396 (II) Furanyl fentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]
397 furan-2-carboxamide);
398 (JJ) Furethidine;
399 (KK) Hydroxypethidine;
400 (LL) Ketobemidone;
401 (MM) Levomoramide;
402 (NN) Levophenacylmorphan;
403 (OO) Methoxyacetyl fentanyl
404 (2-Methoxy-N-(1-phenylethylpiperidinyl-4-yl)-N-acetamide);

405 (PP) Morpheridine;
406 (QQ) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
407 (RR) Noracymethadol;
408 (SS) Norlevorphanol;
409 (TT) Normethadone;
410 (UU) Norpipanone;
411 (VV) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4- piperidinyl]
412 propanamide);
413 (WW) Para-fluoroisobutyryl fentanyl
414 (N-(4-Fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);
415 (XX) PEPAP (1-(2-phenethyl)-4-phenyl-4-acetoxy piperidine);
416 (YY) Phenadoxone;
417 (ZZ) Phenampromide;
418 (AAA) Phenibut;
419 (BBB) Phenomorphan;
420 (CCC) Phenoperidine;
421 (DDD) Piritramide;
422 (EEE) Proheptazine;
423 (FFF) Properidine;
424 (GGG) Propiram;
425 (HHH) Racemoramide;
426 (III) Tetrahydrofuran fentanyl
427 (N-(1-Phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide);
428 (JJJ) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]- propanamide;
429 (KKK) Tianeptine;
430 (LLL) Tilidine;
431 (MMM) Trimeperidine;
432 (NNN) 3-methylfentanyl, including the optical and geometric isomers
433 (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]- N-phenylpropanamide);
434 (OOO) 3-methylthiofentanyl
435 (N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
436 (PPP) 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide also
437 known as U-47700; and
438 (QQQ) 4-cyano CUMYL-BUTINACA.

439 (ii) Unless specifically excepted or unless listed in another schedule, any of the
440 following opium derivatives, their salts, isomers, and salts of isomers when the
441 existence of the salts, isomers, and salts of isomers is possible within the specific
442 chemical designation:

443 (A) Acetorphine;
444 (B) Acetyldihydrocodeine;
445 (C) Benzylmorphine;
446 (D) Codeine methylbromide;
447 (E) Codeine-N-Oxide;
448 (F) Cyprenorphine;
449 (G) Desomorphine;
450 (H) Dihydromorphine;
451 (I) Drotebanol;
452 (J) Etorphine (except hydrochloride salt);
453 (K) Heroin;
454 (L) Hydromorphenol;
455 (M) Methyldesorphine;
456 (N) Methylhydromorphone;
457 (O) Morphine methylbromide;
458 (P) Morphine methylsulfonate;
459 (Q) Morphine-N-Oxide;
460 (R) Myrophine;
461 (S) Nicocodeine;
462 (T) Nicomorphine;
463 (U) Normorphine;
464 (V) Pholcodine; and
465 (W) Thebacon.

466 (iii) Unless specifically excepted or unless listed in another schedule, any material,
467 compound, mixture, or preparation which contains any quantity of the following
468 hallucinogenic substances, or which contains any of their salts, isomers, and salts
469 of isomers when the existence of the salts, isomers, and salts of isomers is possible
470 within the specific chemical designation; as used in this Subsection (2)(a)(iii)
471 only, "isomer" includes the optical, position, and geometric isomers:

472 (A) Alpha-ethyltryptamine, some trade or other names: etryptamine; Monase; α

473 -ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; α -ET; and AET;

474 (B) 4-bromo-2,5-dimethoxy-amphetamine, some trade or other names:

475 4-bromo-2,5-dimethoxy- α -methylphenethylamine; 4-bromo-2,5-DMA;

476 (C) 4-bromo-2,5-dimethoxyphenethylamine, some trade or other names:

477 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB;

478 2C-B, Nexus;

479 (D) 2,5-dimethoxyamphetamine, some trade or other names: 2,5-dimethoxy- α

480 -methylphenethylamine; 2,5-DMA;

481 (E) 2,5-dimethoxy-4-ethylamphetamine, some trade or other names: DOET;

482 (F) 4-methoxyamphetamine, some trade or other names: 4-methoxy- α

483 -methylphenethylamine; paramethoxyamphetamine, PMA;

484 (G) 5-methoxy-3,4-methylenedioxymphetamine;

485 (H) 4-methyl-2,5-dimethoxy-amphetamine, some trade and other names:

486 4-methyl-2,5-dimethoxy- α -methylphenethylamine; "DOM"; and "STP";

487 (I) 3,4-methylenedioxymphetamine;

488 (J) 3,4-methylenedioxymethamphetamine (MDMA);

489 (K) 3,4-methylenedioxymethylamphetamine, also known as N-ethyl-

490 alpha-methyl-3,4(methylenedioxymethyl)phenethylamine, N-ethyl MDA, MDE,

491 MDEA;

492 (L) N-hydroxy-3,4-methylenedioxymphetamine, also known as

493 N-hydroxy-alpha-methyl-3,4(methylenedioxymethyl)phenethylamine, and N-hydroxy

494 MDA;

495 (M) 3,4,5-trimethoxyamphetamine;

496 (N) Bufotenine, some trade and other names: 3-(β

497 -Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol;

498 N, N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine;

499 (O) Diethyltryptamine, some trade and other names: N,N-Diethyltryptamine; DET;

500 (P) Dimethyltryptamine, some trade or other names: DMT;

501 (Q) Ibogaine, some trade and other names: 7-Ethyl-6,6 β

502 ,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido [1', 2':1,2]

503 azepino [5,4-b] indole; Tabernanthe iboga;

504 (R) Lysergic acid diethylamide;

505 (S) Marijuana;

506 (T) Mescaline;

507 (U) Parahexyl, some trade or other names:
508 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran;
509 Synhexyl;

510 (V) Peyote, meaning all parts of the plant presently classified botanically as
511 Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any
512 extract from any part of such plant, and every compound, manufacture, salts,
513 derivative, mixture, or preparation of such plant, its seeds or extracts
514 (Interprets 21 USC 812(c), Schedule I(c) (12));

515 (W) N-ethyl-3-piperidyl benzilate;

516 (X) N-methyl-3-piperidyl benzilate;

517 (Y) Psilocybin;

518 (Z) Psilocyn;

519 (AA) Tetrahydrocannabinols, naturally contained in a plant of the genus Cannabis
520 (cannabis plant), except for marijuana as defined in Subsection 58-37-2
521 (1)(aa)(i)(E), as well as synthetic equivalents of the substances contained in the
522 cannabis plant, or in the resinous extractives of Cannabis, sp. and/or synthetic
523 substances, derivatives, and their isomers with similar chemical structure and
524 pharmacological activity to those substances contained in the plant, such as the
525 following: Δ 1 cis or trans tetrahydrocannabinol, and their optical isomers Δ 6 cis or
526 trans tetrahydrocannabinol, and their optical isomers Δ 3,4 cis or trans
527 tetrahydrocannabinol, and its optical isomers, and since nomenclature of these
528 substances is not internationally standardized, compounds of these structures,
529 regardless of numerical designation of atomic positions covered;

530 (BB) Ethylamine analog of phencyclidine, some trade or other names:
531 N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl)ethylamine,
532 N-(1-phenylcyclohexyl)ethylamine, cyclohexamine, PCE;

533 (CC) Pyrrolidine analog of phencyclidine, some trade or other names:
534 1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP;

535 (DD) Thiophene analog of phencyclidine, some trade or other names:
536 1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienyl analog of phencyclidine,
537 TPCP, TCP; and

538 (EE) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine, some other names: TCPy.

539 (iv) Unless specifically excepted or unless listed in another schedule, any material
540 compound, mixture, or preparation which contains any quantity of the following

541 substances having a depressant effect on the central nervous system, including its
542 salts, isomers, and salts of isomers when the existence of the salts, isomers, and
543 salts of isomers is possible within the specific chemical designation:

544 (A) Mecloqualone; and
545 (B) Methaqualone.

546 (v) Any material, compound, mixture, or preparation containing any quantity of the
547 following substances having a stimulant effect on the central nervous system,
548 including their salts, isomers, and salts of isomers:

549 (A) Aminorex, some other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline;
550 or 4,5-dihydro-5-phenyl-2-oxazolamine;
551 (B) Cathinone, some trade or other names: 2-amino-1-phenyl-1-propanone,
552 alpha-aminopropiophenone, 2-aminopropiophenone, and norephedrone;
553 (C) Fenethylline;
554 (D) Methcathinone, some other names: 2-(methylamino)-propiophenone;
555 alpha-(methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one;
556 alpha-N-methylaminopropiophenone; monomethylpropion; ephedrone;
557 N-methylcathinone; methylcathinone; AL-464; AL-422; AL-463 and UR1432,
558 its salts, optical isomers, and salts of optical isomers;
559 (E) (\pm) cis-4-methylaminorex ((\pm) cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);
560 (F) N-ethylamphetamine; and
561 (G) N,N-dimethylamphetamine, also known as
562 N,N-alpha-trimethyl-benzeneethanamine; N,N-alpha-trimethylphenethylamine.

563 (vi) Any material, compound, mixture, or preparation which contains any quantity of
564 the following substances, including their optical isomers, salts, and salts of
565 isomers, subject to temporary emergency scheduling:

566 (A) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl); and
567 (B) N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl).

568 (vii) Unless specifically excepted or unless listed in another schedule, any material,
569 compound, mixture, or preparation which contains any quantity of gamma
570 hydroxy butyrate (gamma hydrobutyric acid), including its salts, isomers, and
571 salts of isomers.

572 (viii) Unless specifically excepted or unless listed in another schedule, the following
573 substances commonly found in *Mitragyna speciosa*, including synthetic versions,
574 isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, when the

existence of the isomers, esters, ethers, and salts is possible within the specific chemical designation:

(A) 7-hydroxymitragynine (methyl)

(E)-2[(2S,3S,7aS,12bS)-3-ethyl-7a-hydroxy-8-methoxy-2,3,4,6,7,12b-hexahydro-1H-indolo[2,3-a]quinolizin-2-yl]-3-methoxyprop-2-enoate},

that is concentrated at a level greater than .4% of the total kratom alkaloid composition of any substance or product; and

(B) Mitragynine pseudoindoxyl (methyl)

(E)-2-[(2S,6'S,7'S,8'aS)-6'-ethyl-4-methoxy-3-oxospiro[1H-indole-2,1'-3,5,6,7,8,8a-hexahydro-2H-indolizine]-7'-yl]-3-methoxyprop-2-enoate).

(b) Schedule II:

(i) Unless specifically excepted or unless listed in another schedule, any of the following substances whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis:

(A) Opium and opiate, and any salt, compound, derivative, or preparation of

opium or opiate, excluding apomorphine, dextrorphan, nalbuphine, nalmefene, naloxone, and naltrexone, and their respective salts, but including:

(I) Raw opium;

(II) Opium extracts;

(III) Opium fluid;

(IV) Powdered opium;

(V) Granulated opium;

(VI) Tincture o

(VII) Codeine;

(VIII) Ethylmorphin

(IX) Etorphine hydrochloride

(X) Hydrocodone;

(XI) Hydromorphone;

(XII) Metopon;

(XIII) Morphine

(XIV) Oxycodone:

(XV) Oxymorphone; and

(XVI) Thebaine;

607 (B) Any salt, compound, derivative, or preparation which is chemically equivalent
608 or identical with any of the substances referred to in Subsection (2)(b)(i)(A),
609 except that these substances may not include the isoquinoline alkaloids of
610 opium;

611 (C) Opium poppy and poppy straw;

612 (D) Coca leaves and any salt, compound, derivative, or preparation of coca leaves,
613 and any salt, compound, derivative, or preparation which is chemically
614 equivalent or identical with any of these substances, and includes cocaine and
615 ecgonine, their salts, isomers, derivatives, and salts of isomers and derivatives,
616 whether derived from the coca plant or synthetically produced, except the
617 substances may not include decocainized coca leaves or extraction of coca
618 leaves, which extractions do not contain cocaine or ecgonine; and

619 (E) Concentrate of poppy straw, which means the crude extract of poppy straw in
620 either liquid, solid, or powder form which contains the phenanthrene alkaloids
621 of the opium poppy.

622 (ii) Unless specifically excepted or unless listed in another schedule, any of the
623 following opiates, including their isomers, esters, ethers, salts, and salts of
624 isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and
625 salts is possible within the specific chemical designation, except dextrorphan and
626 levopropoxyphene:

627 (A) Alfentanil;

628 (B) Alphaprodine;

629 (C) Anileridine;

630 (D) Bezetramide;

631 (E) Bulk dextropropoxyphene (nondosage forms);

632 (F) Carfentanil;

633 (G) Dihydrocodeine;

634 (H) Diphenoxylate;

635 (I) Fentanyl;

636 (J) Isomethadone;

637 (K) Levo-alpha-acetylmethadol, some other names: levo-alpha-acetylmethadol,
638 levomethadyl acetate, or LAAM;

639 (L) Levomethorphan;

640 (M) Levorphanol;

641 (N) Metazocine;
642 (O) Methadone;
643 (P) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;
644 (Q) Moramide-Intermediate, 2-methyl-3-morpholino-1,
645 1-diphenylpropane-carboxylic acid;
646 (R) Pethidine (meperidine);
647 (S) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
648 (T) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
649 (U) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
650 (V) Phenazocine;
651 (W) Piminodine;
652 (X) Racemethorphan;
653 (Y) Racemorphan;
654 (Z) Remifentanil; and
655 (AA) Sufentanil.

656 (iii) Unless specifically excepted or unless listed in another schedule, any material,
657 compound, mixture, or preparation which contains any quantity of the following
658 substances having a stimulant effect on the central nervous system:
659 (A) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
660 (B) Methamphetamine, its salts, isomers, and salts of its isomers;
661 (C) Phenmetrazine and its salts; and
662 (D) Methylphenidate.

663 (iv) Unless specifically excepted or unless listed in another schedule, any material,
664 compound, mixture, or preparation which contains any quantity of the following
665 substances having a depressant effect on the central nervous system, including its
666 salts, isomers, and salts of isomers when the existence of the salts, isomers, and
667 salts of isomers is possible within the specific chemical designation:
668 (A) Amobarbital;
669 (B) Glutethimide;
670 (C) Pentobarbital;
671 (D) Phencyclidine;
672 (E) Phencyclidine immediate precursors: 1-phenylcyclohexylamine and
673 1-piperidinocyclohexanecarbonitrile (PCC); and
674 (F) Secobarbital.

675 (v)(A) Unless specifically excepted or unless listed in another schedule, any
676 material, compound, mixture, or preparation which contains any quantity of
677 Phenylacetone.

678 (B) Some of these substances may be known by trade or other names:
679 phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl ketone.

680 (vi) Nabilone, another name for nabilone: (±
681)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,
682 6-dimethyl-9H-dibenzo[b,d]pyran-9-one.

683 (vii) A drug product or preparation that contains any component of marijuana,
684 including tetrahydrocannabinol, and is approved by the United States Food and
685 Drug Administration and scheduled by the Drug Enforcement Administration in
686 Schedule II of the federal Controlled Substances Act, Title II, P.L. 91-513.

687 (c) Schedule III:
688 (i) Unless specifically excepted or unless listed in another schedule, any material,
689 compound, mixture, or preparation which contains any quantity of the following
690 substances having a stimulant effect on the central nervous system, including its
691 salts, isomers whether optical, position, or geometric, and salts of the isomers
692 when the existence of the salts, isomers, and salts of isomers is possible within the
693 specific chemical designation:
694 (A) Those compounds, mixtures, or preparations in dosage unit form containing
695 any stimulant substances listed in Schedule II, which compounds, mixtures, or
696 preparations were listed on August 25, 1971, as excepted compounds under
697 Section 1308.32 of Title 21 of the Code of Federal Regulations, and any other
698 drug of the quantitative composition shown in that list for those drugs or which
699 is the same except that it contains a lesser quantity of controlled substances;
700 (B) Benzphetamine;
701 (C) Chlorphentermine;
702 (D) Clortermine; and
703 (E) Phendimetrazine.
704 (ii) Unless specifically excepted or unless listed in another schedule, any material,
705 compound, mixture, or preparation which contains any quantity of the following
706 substances having a depressant effect on the central nervous system:
707 (A) Any compound, mixture, or preparation containing amobarbital, secobarbital,
708 pentobarbital, or any salt of any of them, and one or more other active

709 medicinal ingredients which are not listed in any schedule;

710 (B) Any suppository dosage form containing amobarbital, secobarbital, or
711 pentobarbital, or any salt of any of these drugs which is approved by the United
712 States Food and Drug Administration for marketing only as a suppository;

713 (C) Any substance which contains any quantity of a derivative of barbituric acid
714 or any salt of any of them;

715 (D) Chlorhexadol;

716 (E) Buprenorphine;

717 (F) Any drug product containing gamma hydroxybutyric acid, including its salts,
718 isomers, and salts of isomers, for which an application is approved under the
719 federal Food, Drug, and Cosmetic Act, Section 505;

720 (G) Ketamine, its salts, isomers, and salts of isomers, some other names for
721 ketamine: \pm -2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone;

722 (H) Lysergic acid;

723 (I) Lysergic acid amide;

724 (J) Methyprylon;

725 (K) Sulfondiethylmethane;

726 (L) Sulfonethylmethane;

727 (M) Sulfonmethane; and

728 (N) Tiletamine and zolazepam or any of their salts, some trade or other names for
729 a tiletamine-zolazepam combination product: Telazol, some trade or other
730 names for tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone, some trade
731 or other names for zolazepam:
732 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e]
733 [1,4]-diazepin-7(1H)-one, flupyrazapon.

734 (iii) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in
735 a U.S. Food and Drug Administration approved drug product, some other names
736 for dronabinol:

737 (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol,
738 or (-)-delta-9-(trans)-tetrahydrocannabinol.

739 (iv) Nalorphine.

740 (v) Unless specifically excepted or unless listed in another schedule, any material,
741 compound, mixture, or preparation containing limited quantities of any of the
742 following narcotic drugs, or their salts calculated as the free anhydrous base or

743 alkaloid:

744 (A) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90
745 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline
746 alkaloid of opium;

747 (B) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90
748 milligrams per dosage unit, with one or more active non-narcotic ingredients in
749 recognized therapeutic amounts;

750 (C) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not
751 more than 15 milligrams per dosage unit, with a fourfold or greater quantity of
752 an isoquinoline alkaloid of opium;

753 (D) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not
754 more than 15 milligrams per dosage unit, with one or more active, non-narcotic
755 ingredients in recognized therapeutic amounts;

756 (E) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more
757 than 90 milligrams per dosage unit, with one or more active non-narcotic
758 ingredients in recognized therapeutic amounts;

759 (F) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more
760 than 15 milligrams per dosage unit, with one or more active, non-narcotic
761 ingredients in recognized therapeutic amounts;

762 (G) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams,
763 or not more than 25 milligrams per dosage unit, with one or more active,
764 non-narcotic ingredients in recognized therapeutic amounts; and

765 (H) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams
766 with one or more active, non-narcotic ingredients in recognized therapeutic
767 amounts.

768 (vi) Unless specifically excepted or unless listed in another schedule, anabolic
769 steroids including any of the following or any isomer, ester, salt, or derivative of
770 the following that promotes muscle growth:

771 (A) Boldenone;

772 (B) Chlorotestosterone (4-chlortestosterone);

773 (C) Clostebol;

774 (D) Dehydrochlormethyltestosterone;

775 (E) Dihydrotestosterone (4-dihydrotestosterone);

776 (F) Drostanolone;

777 (G) Ethylestrenol;
778 (H) Fluoxymesterone;
779 (I) Formebulone (formeboleone);
780 (J) Mesterolone;
781 (K) Methandienone;
782 (L) Methandranone;
783 (M) Methandriol;
784 (N) Methandrostenolone;
785 (O) Methenolone;
786 (P) Methyltestosterone;
787 (Q) Mibolerone;
788 (R) Nandrolone;
789 (S) Norethandrolone;
790 (T) Oxandrolone;
791 (U) Oxymesterone;
792 (V) Oxymetholone;
793 (W) Stanolone;
794 (X) Stanozolol;
795 (Y) Testolactone;
796 (Z) Testosterone; and
797 (AA) Trenbolone.

798 (vii) Anabolic steroids expressly intended for administration through implants to
799 cattle or other nonhuman species, and approved by the Secretary of Health and
800 Human Services for use, may not be classified as a controlled substance.

801 (viii) A drug product or preparation that contains any component of marijuana,
802 including tetrahydrocannabinol, and is approved by the United States Food and
803 Drug Administration and scheduled by the Drug Enforcement Administration in
804 Schedule III of the federal Controlled Substances Act, Title II, P.L. 91-513.

805 (ix) Nabiximols.

806 (d) Schedule IV:

807 (i) Unless specifically excepted or unless listed in another schedule, any material,
808 compound, mixture, or preparation containing not more than 1 milligram of
809 difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit, or
810 any salts of any of them.

811 (ii) Unless specifically excepted or unless listed in another schedule, any material,
812 compound, mixture, or preparation which contains any quantity of the following
813 substances, including its salts, isomers, and salts of isomers when the existence of
814 the salts, isomers, and salts of isomers is possible within the specific chemical
815 designation:

816 (A) Alprazolam;
817 (B) Barbital;
818 (C) Bromazepam;
819 (D) Butorphanol;
820 (E) Camazepam;
821 (F) Carisoprodol;
822 (G) Chloral betaine;
823 (H) Chloral hydrate;
824 (I) Chlordiazepoxide;
825 (J) Clobazam;
826 (K) Clonazepam;
827 (L) Clorazepate;
828 (M) Clotiazepam;
829 (N) Cloxazolam;
830 (O) Delorazepam;
831 (P) Diazepam;
832 (Q) Dichloralphenazone;
833 (R) Estazolam;
834 (S) Ethchlorvynol;
835 (T) Ethinamate;
836 (U) Ethyl loflazepate;
837 (V) Fludiazepam;
838 (W) Flunitrazepam;
839 (X) Flurazepam;
840 (Y) Halazepam;
841 (Z) Haloxazolam;
842 (AA) Ketazolam;
843 (BB) Loprazolam;
844 (CC) Lorazepam;

845 (DD) Lormetazepam;
846 (EE) Mebutamate;
847 (FF) Medazepam;
848 (GG) Meprobamate;
849 (HH) Methohexital;
850 (II) Methylphenobarbital (mephobarbital);
851 (JJ) Midazolam;
852 (KK) Nimetazepam;
853 (LL) Nitrazepam;
854 (MM) Nordiazepam;
855 (NN) Oxazepam;
856 (OO) Oxazolam;
857 (PP) Paraldehyde;
858 (QQ) Pentazocine;
859 (RR) Petrichloral;
860 (SS) Phenobarbital;
861 (TT) Pinazepam;
862 (UU) Prazepam;
863 (VV) Quazepam;
864 (WW) Temazepam;
865 (XX) Tetrazepam;
866 (YY) Tramadol;
867 (ZZ) Triazolam;
868 (AAA) Zaleplon; and
869 (BBB) Zolpidem.

870 (iii) Any material, compound, mixture, or preparation of fenfluramine which contains
871 any quantity of the following substances, including its salts, isomers whether
872 optical, position, or geometric, and salts of the isomers when the existence of the
873 salts, isomers, and salts of isomers is possible.

874 (iv) Unless specifically excepted or unless listed in another schedule, any material,
875 compound, mixture, or preparation which contains any quantity of the following
876 substances having a stimulant effect on the central nervous system, including its
877 salts, isomers whether optical, position, or geometric isomers, and salts of the
878 isomers when the existence of the salts, isomers, and salts of isomers is possible

879 within the specific chemical designation:

880 (A) Cathine ((+)-norpseudoephedrine);

881 (B) Diethylpropion;

882 (C) Fencamfamine;

883 (D) Fenproporex;

884 (E) Mazindol;

885 (F) Mefenorex;

886 (G) Modafinil;

887 (H) Pemoline, including organometallic complexes and chelates thereof;

888 (I) Phentermine;

889 (J) Pipradrol;

890 (K) Sibutramine; and

891 (L) SPA ((-)-1-dimethylamino-1,2-diphenylethane).

892 (v) Unless specifically excepted or unless listed in another schedule, any material,

893 compound, mixture, or preparation which contains any quantity of

894 dextropropoxyphene (alpha-(+)-4-dimethylamino-1,

895 2-diphenyl-3-methyl-2-propionoxybutane), including its salts.

896 (vi) A drug product or preparation that contains any component of marijuana and is

897 approved by the United States Food and Drug Administration and scheduled by

898 the Drug Enforcement Administration in Schedule IV of the federal Controlled

899 Substances Act, Title II, P.L. 91-513.

900 (e) Schedule V:

901 (i) Any compound, mixture, or preparation containing any of the following limited

902 quantities of narcotic drugs, or their salts calculated as the free anhydrous base or

903 alkaloid, which includes one or more non-narcotic active medicinal ingredients in

904 sufficient proportion to confer upon the compound, mixture, or preparation

905 valuable medicinal qualities other than those possessed by the narcotic drug alone:

906 (A) not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;

907 (B) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100

908 grams;

909 (C) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100

910 grams;

911 (D) not more than 2.5 milligrams of diphenoxylate and not less than 25

912 micrograms of atropine sulfate per dosage unit;

913 (E) not more than 100 milligrams of opium per 100 milliliters or per 100 grams;
914 (F) not more than 0.5 milligram of difenoxin and not less than 25 micrograms of
915 atropine sulfate per dosage unit; and
916 (G) unless specifically exempted or excluded or unless listed in another schedule,
917 any material, compound, mixture, or preparation which contains Pyrovalerone
918 having a stimulant effect on the central nervous system, including its salts,
919 isomers, and salts of isomers.

920 (ii) A drug product or preparation that contains any component of marijuana,
921 including cannabidiol, and is approved by the United States Food and Drug
922 Administration and scheduled by the Drug Enforcement Administration in
923 Schedule V of the federal Controlled Substances Act, Title II, P.L. 91-513.

924 (iii) Gabapentin.

925 **Section 4. Effective Date.**

926 This bill takes effect:

927 (1) except as provided in Subsection (2), May 6, 2026; or
928 (2) if approved by two-thirds of all members elected to each house:
929 (a) upon approval by the governor;
930 (b) without the governor's signature, the day following the constitutional time limit of
931 Utah Constitution, Article VII, Section 8; or
932 (c) in the case of a veto, the date of veto override.